Dietary supplement s-adenosyl-l-methionine (AdoMet) effects on plasma homocysteine levels in healthy human subjects: A double-blind, placebo-controlled, randomized clinical trial

Journal of Alternative and Complementary Medicine

Volumn 15, Issue 5, 2009, Pages 523-529

  Thompson, Michael A ^a,b   Bauer, Brent A ^a   Loehrer, Laura L ^a   Cha, Stephen S ^a   Mandrekar, Jayawant N ^a   Sood, Amit ^a   Wahner Roedler, Dietlind L ^a  

^a MAYO CLINIC   (United States)

^b Waukesha Memorial Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOMET; ALANINE AMINOTRANSFERASE; C REACTIVE PROTEIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; HOMOCYSTEINE; PLACEBO; S ADENOSYLMETHIONINE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; AMINO ACID BLOOD LEVEL; ANOREXIA; ARTICLE; BLOATING; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; FATIGUE; FEMALE; FLATULENCE; HUMAN; INSOMNIA; LIPOPROTEIN BLOOD LEVEL; MALE; MIGRAINE; NAUSEA; NORMAL HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; URINARY FREQUENCY; WEIGHT GAIN; XEROSTOMIA;

ADOLESCENT; ADULT; ALANINE TRANSAMINASE; C-REACTIVE PROTEIN; CHOLESTEROL; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FEMALE; HOMOCYSTEINE; HUMANS; MALE; MIDDLE AGED; S-ADENOSYLMETHIONINE; YOUNG ADULT;

EID: 67149105905     PISSN: 10755535     EISSN: None     Source Type: Journal    
DOI: 10.1089/acm.2008.0402     Document Type: Article

References (36)

1. Balluz LS, Kieszak SM, Philen RM, Mulinare J. Vitamin and mineral supplement use in the United States: Results from the third National Health and Nutrition Examination Survey. Arch Fam Med 2000;9:258-262. Erratum in Arch Fam Med 2000;9:652.
2. Ervin RB, Wright JD, Kennedy-Stephenson J. Use of dietary supplements in the United States, 1988-94. Vital Health Stat 11. 1999;244:i-iii, 1-14.
3. Barnes PM, Powell-Griner E, McFann K, Nahin RL. Complementary and alternative medicine use among adults: United States, 2002. Adv Data 2004;343:1-19.
4. Jacobsen S, Danneskiold-Samsøe B, Andersen RB. Oral S-adenosylmethionine in primary fibromyalgia: Double-blind clinical evaluation. Scand J Rheumatol 1991;20:294-302.
5. S-Adenosyl-l-Methionine for Treatment of Depression, Osteoarthritis, and Liver Disease. Summary, Evidence Report/Technology Assessment: Number 64. Publication No. 02-E033. Rockville, MD: Agency for Healthcare Research and Quality, 2002.
6. Bottiglieri T. S-Adenosyl-l-methionine (SAMe): From the bench to the bedside: molecular basis of a pleiotrophic molecule. Am J Clin Nutr 2002;76:1151S-1157S.
7. Cohen J. Statistical power and analysis for the behavioral sciences, Rev. ed. New York: Academic Press, 1977.
8. Loehrer FM, Schwab R, Angst CP, Haefeli WE, Fowler B. Influence of oral S-adenosylmethionine on plasma 5-methyltetrahydrofolate, S-adenosylhomocysteine, homocysteine and methionine in healthy humans. J Pharmacol Exp Ther 1997;282:845-850.
9. Fetrow CW, Avila JR. Efficacy of the dietary supplement S-adenosyl-l-methionine. Ann Pharmacother 2001;35:1414 - 1425.
10. SAMe for depression. Med Lett Drugs Ther 1999;41:107-108.
11. Mischoulon D, Fava M. Role of S-adenosyl-l-methionine in the treatment of depression: A review of the evidence. Am J Clin Nutr 2002;76:1158S-1161S.
12. Friedel HA, Goa KL, Benfield P. S-adenosyl-l-methionine: A review of its pharmacological properties and therapeutic potential in liver dysfunction and affective disorders in relation to its physiological role in cell metabolism. Drugs 1989;38:389-416.
13. Lipinski JF, Cohen BM, Frankenburg FT, et al. Open trial of S-adenosylmethionine for treatment of depression. Am J Psychiatry 1984;141:448-450.
14. Magera MJ, Lacey JM, Casetta B, Rinaldo P. Method for the determination of total homocysteine in plasma and urine by stable isotope dilution and electrospray tandem mass spectrometry. Clin Chem 1999;45:1517-1522.
15. Gören JL, Stoll AL, Damico KE, Sarmiento IA, Cohen BM. Bioavailability and lack of toxicity of S-adenosyl-l-methionine (SAMe) in humans. Pharmacotherapy 2004;24:1501-1507.
16. Chawla RK, Lewis FW, Kutner MH, Bate DM, Roy RG, Rudman D. Plasma cysteine, cystine, and glutathione in cirrhosis. Gastroenterology 1984;87:770-776.
17. Williams R, Lieber CS. The role of SAMe in the treatment of liver disease. Drugs 1990;40(Suppl 3):S1-S2.
18. Almasio P, Bortolini M, Pagliaro L, Coltorti M. Role of S-adenosyl-l-methionine in the treatment of intrahepatic cholestasis. Drugs 1990;40(Suppl 3):S111-S123.
19. Milkiewicz P, Mills CO, Roma MG, Ahmed-Choudhury J, Elias E, Coleman R. Tauroursodeoxycholate and S-adenosyl-l-methionine exert an additive ameliorating effect on taurolithocholate-induced cholestasis: A study in isolated rat hepatocyte couplets. Hepatology 1999;29:471-476.
20. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: Probable benefits of increasing folic acid intakes. JAMA 1995;274:1049-1057.
21. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: A meta-analysis. JAMA 2002;288:2015-2022.
22. Bots ML, Launer LJ, Lindemans J, Hofman A, Grobbee DE. Homocysteine, atherosclerosis and prevalent cardiovascular disease in the elderly: The Rotterdam Study. J Intern Med 1997;242:339-347.
23. Malinow MR, Bostom AG, Krauss RM. Homocyst(e)ine, diet, and cardiovascular diseases: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation 1999;99:178-182.
24. Stampfer MJ, Malinow MR, Willett WC, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992;268:877-881.
25. Selhub J, Jacques PF, Bostom AG, et al. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med 1995;332:286-291.
26. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 1995;346:1395-1398.
27. den Heijer M, Koster T, Blom HJ, et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996;334:759-762.
28. Schnyder G, Roffi M, Pin R, et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 2001;345:1593-1600.
29. Schnyder G, Pin R, Roffi M, Flammer Y, Hess OM. Association of plasma homocysteine with the number of major coronary arteries severely narrowed. Am J Cardiol 2001;88:1027-1030.
30. Schnyder G, Roffi M, Flammer Y, Pin R, Hess OM. Association of plasma homocysteine with restenosis after percutaneous coronary angioplasty. Eur Heart J 2002;23:726-733.
31. 6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart study: A randomized controlled trial. JAMA 2002;288:973-979.
32. Schnyder G, Roffi M, Flammer Y, et al. Effect of homocysteine-lowering therapy on restenosis after percutaneous coronary intervention for narrowings in small coronary arteries. Am J Cardiol 2003;91:1265-1269.
33. Lonn E, Yusuf S, Arnold MJ, et al., Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006;354:1567-1577. Erratum in N Engl J Med 2006;355:746.
34. Bønaa KH, Njølstad I, Ueland PM, et al., NORVIT Trial Investigators. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006;354:1578-1588.
35. McMahon JA, Green TJ, Skeaff CM, Knight RG, Mann JI, Williams SM. A controlled trial of homocysteine lowering and cognitive performance. N Engl J Med 2006;354:2764-2772.
36. Fuso A, Seminara L, Cavallaro RA, D'Anselmi F, Scarpa S. S-adenosylmethionine/homocysteine cycle alterations modify DNA methylation status with consequent deregulation of PS1 and BACE and beta-amyloid production. Mol Cell Neurosci 2005;28:195-204. Erratum in Mol Cell Neurosci 2006;32:419.